A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab

SUMMARY: This phase 2 study evaluated the efficacy and safety of transitioning to zoledronate following romosozumab treatment in postmenopausal women with low bone mass. A single dose of 5 mg zoledronate generally maintained the robust BMD gains accrued with romosozumab treatment and was well tolera...

Descripción completa

Detalles Bibliográficos
Autores principales: McClung, M. R., Bolognese, M. A., Brown, J. P., Reginster, J.-Y., Langdahl, B. L., Maddox, J., Shi, Y., Rojeski, M., Meisner, P. D., Grauer, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer London 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7560921/
https://www.ncbi.nlm.nih.gov/pubmed/32623487
http://dx.doi.org/10.1007/s00198-020-05502-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7560921/
https://www.ncbi.nlm.nih.gov/pubmed/32623487
http://dx.doi.org/10.1007/s00198-020-05502-0

Ejemplares similares